CDK4 and breast carcinoma: Remarkably, employment of D 4476 potentiates the efficacy of ribociclib in inhibiting RB1 phosphorylation in multiple CDK4/6i resistant breast cancer cells, accompanied with antagonizing CDK4/6i treatment induced CDK6 protein accumulation (Fig. 7c, Supplementary Fig. 7a).